citizen watches riva
Public Citizen Names Two Groups For Whom Fosamax Has No Benefit of Therapy
Bone-strengthening drug Fosamax became a blockbuster medicine in the United States and the rest of North America because of the millions of Americans dealing with osteoporosis. Although this bisphosphonate works in wonder against osteoporosis, it also carries undesirable effects, including a risk for osteonecrosis of the jaw. But what is osteonecrosis of the jaw and what must people in the world need to know about this severe dental problem?
Not so long ago, the food and drug Administration (FDA) addressed the issue about doctors less cautiously ordering bisphosphonates to their patients. Consumer advocacy group Public Citizen named two groups who are not getting any benefits from Fosamax therapy. These populations who may be unnecessarily taking the drug are also putting themselves at risk of this jaw bone problem.
Osteonecrosis of the jaw, commonly referred to as ONJ or “dead jaw,” is a disease characterized by an exposure of the jawbone. This bone tissue does not receive enough blood supply, which eventually causes its death or necrosis. The terms “Bis-Phossy Jaw” and BON are invented by scientists who refer to ONJ as having been brought by the use of bisphosphonates, such as Fosamax.
In the first stage of ONJ, patient would appear to have no symptoms until the disease develops, in which one could feel pain, swelling and redness usually associated with gum infection. ONJ is often diagnosed by the presence of exposed bone tissue, which more often lasts for more than eight weeks. Additionally, the condition may be worsened by dental procedures like tooth extraction.
ONJ is generally treated with non-surgical approach consisting of antimicrobial rinses, systemic antibiotics, systemic or topical antifungal treatment and pain relievers. In its advanced stage surgical debridement or resection may be necessary, along with other nonsurgical interventions. It is best for anyone to let the dentist know if he or she is on bisphosphonate therapy before any dental procedures or even minor surgeries are performed.
In July 2005, Merck changed the label of Fosamax regarding ONJ risk as ordered by FDA. Nonetheless, several long-term Fosamax patronizers claimed that Merck lacked proper disclosure of the said risk causing them to agonize such side effect and other backlash. Consequently the affected parties initiated the filing of Fosamax lawsuit against the maker of the drug.
Citizen Watches Riva 7336546
We appreciate you taking the time to visit our website
and hope that we were able to help you in your search for the information that you are looking for.
We do realize that with so many articles written, it is possible
and even likely that you will find mistakes along the way.
We would greatly appreciate you using the "contact us" page to let us know if you come across any mistakes
in our articles or if you simply have some ideas for articles that you would like to see in the future.
Thanks again for taking the time to visit,
we hope you have enjoyed you stay and hope that you will visit us again someday very soon.
